Role of FDG-PET/CT in Prediction of Underestimation of Invasive Breast Cancer in Cases of Ductal Carcinoma In Situ Diagnosed at Needle Biopsy

Shigematsu, Hideo; Kadoya, Takayuki; Masumoto, Norio; Matsuura, Kazuo; Emi, Akiko; Kajitani, Keiko; Amioka, Ai; Okada, Minoru

doi:10.1016/j.clbc.2014.04.006

Cited by 11 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the ideal time for FDG PET and BSGI being before biopsy in order to exclude an inflammatory effect caused by the invasive procedure, most 18 F-FDG PET and BSGI work-ups are performed after pathologic confirmation in the clinical setting. In this study, the minimum time interval for FDG PET after biopsy was two weeks, as was done in a previous study [19]. Additionally, the timing of BSGI after the biopsy procedure followed guidelines [20,21].…”

Section: Discussionmentioning

confidence: 99%

“…One research group recently investigated the role of 18 F-FDG PET/CT and reported the predictive value of SUV max for the underestimation of invasive breast cancer in biopsy-confirmed DCIS [19]. Although SUV max is the most commonly used PET parameter indicating metabolic intensity, an intrinsic property of SUV max is that it reflects only the most aggressive part of the tumour and not the whole tumour, and this has been recognized as a limitation.…”

Section: Discussionmentioning

confidence: 99%

“…18 F-FDG PET/CT and BSGI 18 F-FDG PET/CT was performed after diagnostic confirmation of DCIS for staging work-up. To avoid possible effects caused by invasive procedures, PET studies were performed at least two weeks after the needle biopsy [19]. For PET/CT, patients were fasted for at least six hours before intravenous administration of 5.18 MBq/kg FDG and blood glucose levels were confirmed to be <140 mg/dL.…”

Section: Pathological Evaluationmentioning

confidence: 99%

See 2 more Smart Citations

Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ

Yoon

Kim

2015

Eur Radiol

View full text Add to dashboard Cite

• Preoperative identification of invasion in DCIS is important for axillary nodal management • Higher SUV max and lower AUC-CSH from FDG PET may indicate invasive components of DCIS • Higher TNR and COV from BSGI may indicate invasive components of DCIS • Lower ADC min and higher ADC diff from DWI may indicate invasive components of DCIS • AUC-CSH, an index of metabolic heterogeneity, is an independent predictor for invasive components.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Pathological Evaluationmentioning

confidence: 99%

See 1 more Smart Citation

Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ

Yoon

Kim

2015

Eur Radiol

View full text Add to dashboard Cite

show abstract

“…There exist only few reports regarding the role of FDG-PET in the detection of DCIS of the breast (15)(16)(17), and the standardized uptake value (SUV) pattern of DCIS of the breast on FDG-PET examination is not fully understood. The findings of our previous study, demonstrated (1) the usefulness of FDG-PET for DCIS and (2) that the presence of FDG uptake in the tumor could be considered a predictor for invasive potential in cases with DCIS cases (17).…”

mentioning

confidence: 99%

Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings

Fujii

Yanai

Tokuda

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefore, this modality is unsuitable for predicting pCR (11,12). Positron emission tomography/computed tomography (PET/CT) is considered useful for diagnosing (13) and assessing the prognosis (14,15) of invasive breast cancer. Although it is also useful for assessing treatment effects (16), the specificity of PET/CT for pCR after chemotherapy is low (17) and the procedure is expensive.…”

mentioning

confidence: 99%

Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy

Amioka

Masumoto

Gouda

et al. 2016

Jpn. J. Clin. Oncol.

Self Cite

View full text Add to dashboard Cite

Objective: We aimed to determine whether contrast-enhanced ultrasonography can predict the effects of neoadjuvant chemotherapy on breast cancer. Methods: The clinical responses of 63 consecutive patients with breast cancer (T1-4, N0-1, M0) to neoadjuvant chemotherapy between October 2012 and May 2015 were assessed using contrastenhanced magnetic resonance imaging, positron emission tomography/computed tomography and contrast-enhanced ultrasonography. Perfusion parameters for contrast-enhanced ultrasonography were created from time-intensity curves based on enhancement intensity and temporal changes to objectively evaluate contrast-enhanced ultrasonography findings. The sensitivity, specificity and accuracy of contrast-enhanced ultrasonography, magnetic resonance imaging and positron emission tomography/computed tomography to predict a pathological complete response were compared after confirming the pathological findings of surgical specimens. Results: Twenty-three (36.5%) of the 63 patients achieved pathological complete response. The sensitivity, specificity and accuracy of contrast-enhanced ultrasonography for predicting pathological complete response were 95.7% (82.5-99.2%), 77.5% (69.9-79.5%) and 84.1% (74.5-86.7%). The sensitivity of contrast-enhanced ultrasonography was significantly greater than that of magnetic resonance imaging (95.7 vs. 69.6%, P = 0.047). The specificity and accuracy were significantly greater and tended to be greater, respectively, for contrast-enhanced ultrasonography than positron emission tomography/computed tomography (specificity, 77.5 vs. 52.5%, P = 0.02; accuracy, 84.1 vs. 69.8%, P = 0.057). Conclusions: Contrast-enhanced ultrasonography might serve as a new diagnostic modality when planning therapeutic strategies for patients with breast cancer after neoadjuvant chemotherapy.

show abstract

Role of FDG-PET/CT in Prediction of Underestimation of Invasive Breast Cancer in Cases of Ductal Carcinoma In Situ Diagnosed at Needle Biopsy

Cited by 11 publications

References 22 publications

Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ

Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ

Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings

Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy

Contact Info

Product

Resources

About